Summary & Overview
HCPCS Level II J2323: Injection, natalizumab, 1 mg
HCPCS Level II code J2323 designates a 1 mg unit of natalizumab for injection, a monoclonal antibody used in specialist-administered biologic therapy. Nationally, accurate coding of J2323 is important for claims processing, therapy management, and consistent reporting of biologic drug utilization across outpatient and infusion settings. This code captures the medication component and is commonly billed by infusion centers, specialty clinics, and hospital outpatient departments.
Key payers addressed in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise summary of what J2323 represents clinically, typical sites of service, and which major payers commonly adjudicate claims for natalizumab injections. The publication outlines common billing considerations, payer coverage patterns, and benchmarks where available. It also provides context on how the code integrates with service lines for infusion of biologic therapies and what to expect in terms of billing workflows.
Data not available in the input is noted where applicable, and the content focuses on national implications rather than state-specific rules.
Billing Code Overview
HCPCS Level II code J2323 represents an injection of natalizumab, 1 mg. This code describes the medication unit for natalizumab administered by injection.
-
Service type: Injectable biologic therapy
-
Typical site of service: Infusion center, outpatient clinic, or other healthcare settings where parenteral biologic therapies are administered
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsing-remitting multiple sclerosis who presents to an infusion center for scheduled natalizumab therapy. The medication is billed as J2323 (injection, natalizumab, 1 mg). The workflow begins with verification of prior authorization and insurance eligibility (payors commonly involved include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare). The patient undergoes screening for recent infections, pregnancy status, and infusion contraindications; baseline vital signs and weight are documented. An intravenous access is established by a registered nurse or infusion specialist, the prescribed dose of natalizumab is prepared by the pharmacy per weight-based dosing, and the product is administered per facility protocol over the recommended infusion time. The patient is observed for infusion-related reactions and monitored for 1 hour post-infusion per protocol. Documentation includes the J2323 units administered, lot number, expiration date, site of service (typically an outpatient infusion center or hospital outpatient department), relevant diagnosis code(s), and any applicable modifier(s) such as JW for discarded drug or QX for qualified nonphysician practitioner under a physician’s supervision when applicable. Billing is submitted to the patient’s payer with the appropriate place of service and provider taxonomy.
Coding Specifications
| Modifier | Description | When to Use |
|---|